ES2710675T3 - Chaperonas farmacológicas para el tratamiento de la obesidad - Google Patents
Chaperonas farmacológicas para el tratamiento de la obesidad Download PDFInfo
- Publication number
- ES2710675T3 ES2710675T3 ES15153180T ES15153180T ES2710675T3 ES 2710675 T3 ES2710675 T3 ES 2710675T3 ES 15153180 T ES15153180 T ES 15153180T ES 15153180 T ES15153180 T ES 15153180T ES 2710675 T3 ES2710675 T3 ES 2710675T3
- Authority
- ES
- Spain
- Prior art keywords
- mc4r
- chaperone
- cell
- mutant
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- AMGWVGXWNMORAW-RFEFMQKASA-N O=C([C@@H](C1)NCc2c1cccc2)N[C@H](Cc(cc1)ccc1Cl)C1(N(CC2)CCN2c2c(CN3CCCC3)cccc2)OC1 Chemical compound O=C([C@@H](C1)NCc2c1cccc2)N[C@H](Cc(cc1)ccc1Cl)C1(N(CC2)CCN2c2c(CN3CCCC3)cccc2)OC1 AMGWVGXWNMORAW-RFEFMQKASA-N 0.000 description 1
- PNEWTCHTCFRXRM-NXFCCEIPSA-N O=C([C@@H](Cc(cc1)ccc1Cl)NC1OC1[C@@H](C1)NCc2c1cccc2)N(CC1)CCC1(C[n]1ncnc1)C1CCCCC1 Chemical compound O=C([C@@H](Cc(cc1)ccc1Cl)NC1OC1[C@@H](C1)NCc2c1cccc2)N(CC1)CCC1(C[n]1ncnc1)C1CCCCC1 PNEWTCHTCFRXRM-NXFCCEIPSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
- C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US68764805P | 2005-06-03 | 2005-06-03 | |
US79996806P | 2006-05-12 | 2006-05-12 | |
US11/446,429 US20070021433A1 (en) | 2005-06-03 | 2006-06-02 | Pharmacological chaperones for treating obesity |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2710675T3 true ES2710675T3 (es) | 2019-04-26 |
Family
ID=37499005
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES15153180T Active ES2710675T3 (es) | 2005-06-03 | 2006-06-05 | Chaperonas farmacológicas para el tratamiento de la obesidad |
ES06772163.9T Active ES2676996T3 (es) | 2005-06-03 | 2006-06-05 | Chaperonas farmacológicas para tratar obesidad |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES06772163.9T Active ES2676996T3 (es) | 2005-06-03 | 2006-06-05 | Chaperonas farmacológicas para tratar obesidad |
Country Status (11)
Country | Link |
---|---|
US (3) | US20070021433A1 (de) |
EP (2) | EP2933265B1 (de) |
JP (3) | JP5241490B2 (de) |
KR (1) | KR20080034877A (de) |
AU (1) | AU2006255131B2 (de) |
CA (2) | CA2610860C (de) |
ES (2) | ES2710675T3 (de) |
HK (1) | HK1216256A1 (de) |
IL (2) | IL187806A (de) |
MX (1) | MX2007015225A (de) |
WO (1) | WO2006133098A2 (de) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4079581B2 (ja) * | 2000-08-11 | 2008-04-23 | ユニ・チャーム株式会社 | 使い捨て着用物品 |
US20130102538A1 (en) * | 2010-05-05 | 2013-04-25 | Amicus Therapeutics, Inc. | Method of treating alzheimer's disease using pharmacological chaperones to increase presenilin function and gamma-secretase activity |
CA2801074A1 (en) | 2010-06-04 | 2011-12-08 | Albany Molecular Research, Inc. | Glycine transporter-1 inhibitors, methods of making them, and uses thereof |
WO2012051518A2 (en) * | 2010-10-14 | 2012-04-19 | Amicus Therapeutics, Inc. | Compounds and methods for treating or preventing disease conditions associated with alpha-1-antitrypsin |
US9018395B2 (en) | 2011-01-27 | 2015-04-28 | Université de Montréal | Pyrazolopyridine and pyrazolopyrimidine derivatives as melanocortin-4 receptor modulators |
US8952000B2 (en) | 2011-02-16 | 2015-02-10 | Pivotal Therapeutics Inc. | Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events |
US9119826B2 (en) | 2011-02-16 | 2015-09-01 | Pivotal Therapeutics, Inc. | Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels |
US8951514B2 (en) | 2011-02-16 | 2015-02-10 | Pivotal Therapeutics Inc. | Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels |
US8715648B2 (en) | 2011-02-16 | 2014-05-06 | Pivotal Therapeutics Inc. | Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics |
HRP20211950T1 (hr) | 2011-12-29 | 2022-03-18 | Rhythm Pharmaceuticals, Inc. | Postupak liječenja poremećaja u vezi sa melanokortin-4 receptorom u heterozigotnim nosiocima |
US9744171B2 (en) | 2012-03-06 | 2017-08-29 | Vanderbilt University | Positive allosteric modulators for melanocortin receptors |
US20150150224A1 (en) * | 2012-06-14 | 2015-06-04 | Universite De Montreal | Transgenic mouse models for mc4r |
JPWO2016056606A1 (ja) * | 2014-10-07 | 2017-07-20 | 国立大学法人京都大学 | ベンゾイソチアゾロピリミジン誘導体またはその塩、およびウイルス感染阻害剤ならびに医薬品 |
WO2019162312A1 (en) | 2018-02-20 | 2019-08-29 | Charité - Universitätsmedizin Berlin | Mc4r agonist efficacy in subjects with mc4r deficiencies and impaired nfat signaling |
CN111601935A (zh) | 2018-03-30 | 2020-08-28 | 住友建机株式会社 | 挖土机 |
Family Cites Families (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
US5650489A (en) | 1990-07-02 | 1997-07-22 | The Arizona Board Of Regents | Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof |
JP2507164B2 (ja) | 1990-10-04 | 1996-06-12 | 三菱電機株式会社 | 半導体記憶装置 |
WO1993013768A1 (en) | 1992-01-06 | 1993-07-22 | Ariad Pharmaceuticals, Inc. | Therapeutic uses of thiol-oxidizing agents and sulfhydryl-alkylating agents |
US5344475A (en) | 1993-03-11 | 1994-09-06 | At&T Bell Laboratories | Manufacture of high proof-test optical fiber using sol-gel |
NZ267843A (en) | 1993-05-27 | 1997-10-24 | Selectide Corp | Libraries of synthetic test compound attached to separate phase synthesis supports |
US5585277A (en) | 1993-06-21 | 1996-12-17 | Scriptgen Pharmaceuticals, Inc. | Screening method for identifying ligands for target proteins |
US5679582A (en) | 1993-06-21 | 1997-10-21 | Scriptgen Pharmaceuticals, Inc. | Screening method for identifying ligands for target proteins |
US5691306A (en) | 1993-08-26 | 1997-11-25 | National Research Council Of Canada | Methods of detection and treatment of protein trafficking disorders and increasing secretory protein production |
US5554601A (en) | 1993-11-05 | 1996-09-10 | University Of Florida | Methods for neuroprotection |
US6054556A (en) | 1995-04-10 | 2000-04-25 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Melanocortin receptor antagonists and agonists |
US5731408A (en) | 1995-04-10 | 1998-03-24 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Peptides having potent antagonist and agonist bioactivities at melanocortin receptors |
EP0959877A4 (de) | 1996-04-10 | 2000-08-23 | Univ California | Korrektur der genetischen fehler mittels chemische begleiter |
US6270954B1 (en) | 1996-04-10 | 2001-08-07 | The Regents Of The University Of California | Correction of genetic defects using chemical chaperones |
US6036920A (en) | 1996-05-09 | 2000-03-14 | 3-Dimensional Pharmaceuticals, Inc. | Microplate thermal shift assay apparatus for ligand development and multi-variable protein chemistry optimization |
US5766877A (en) | 1996-05-10 | 1998-06-16 | Amgen Inc. | Genes encoding art, an agouti-related transcript |
WO1997045730A1 (en) | 1996-05-30 | 1997-12-04 | Biodx | Miniaturized cell array methods and apparatus for cell-based screening |
US6103479A (en) | 1996-05-30 | 2000-08-15 | Cellomics, Inc. | Miniaturized cell array methods and apparatus for cell-based screening |
US5985824A (en) * | 1997-02-27 | 1999-11-16 | Genzyme Corporation | Methods and compositions for treating cystic fibrosis |
JP3683591B2 (ja) | 1997-02-27 | 2005-08-17 | セロミックス インコーポレイテッド | 細胞に基づくスクリーニングシステム |
AU3768799A (en) | 1998-04-28 | 1999-11-16 | Trega Biosciences, Inc. | Isoquinoline compound melanocortin receptor ligands and methods of using same |
US6274597B1 (en) | 1998-06-01 | 2001-08-14 | Mount Sinai School Of Medicine Of New York University | Method of enhancing lysosomal α-Galactosidase A |
EP1085869A4 (de) | 1998-06-11 | 2001-10-04 | Merck & Co Inc | Spiro piperidinderivate als melanocortinrezeptoragonisten |
US6406921B1 (en) | 1998-07-14 | 2002-06-18 | Zyomyx, Incorporated | Protein arrays for high-throughput screening |
GB9816514D0 (en) | 1998-07-29 | 1998-09-30 | Smithkline Beecham Plc | Novel method |
US6197599B1 (en) | 1998-07-30 | 2001-03-06 | Guorong Chin | Method to detect proteins |
US6344475B1 (en) * | 1998-10-27 | 2002-02-05 | Yale University | Conductance of improperly folded proteins through the secretory pathway |
EE200100302A (et) * | 1998-12-02 | 2002-08-15 | Pfizer Products Inc. | Meetodid ja kompositsioonid p53 perekonna valgu konformatsioonilise stabiilsuse taastamiseks |
ATE393783T1 (de) | 1999-03-29 | 2008-05-15 | Procter & Gamble | Melanocortinrezeptor-liganden |
US7375125B2 (en) * | 1999-08-04 | 2008-05-20 | Ore Pharmaceuticals, Inc. | Melanocortin-4 receptor binding compounds and methods of use thereof |
JP2003528810A (ja) * | 1999-08-04 | 2003-09-30 | ミレニアム ファーマスーティカルズ インク | メラノコルチン−4受容体結合化合物及びその使用方法 |
US6699873B1 (en) | 1999-08-04 | 2004-03-02 | Millennium Pharmaceuticals, Inc. | Melanocortin-4 receptor binding compounds and methods of use thereof |
US20020197656A1 (en) | 1999-12-17 | 2002-12-26 | Ronghao Li | Cell arrays and the uses thereof |
US6406840B1 (en) | 1999-12-17 | 2002-06-18 | Biomosaic Systems, Inc. | Cell arrays and the uses thereof |
EE200200717A (et) | 2000-06-27 | 2004-08-16 | Taisho Pharmaceutical Co., Ltd. | Ravimpreparaat ängistusneuroosi või depressiooni raviks ja piperasiiniderivaadid |
DZ3415A1 (fr) | 2000-08-31 | 2002-03-07 | Chiron Corp | Guanidinobenzamides comme mc4-r agonistes. |
US20020115619A1 (en) | 2000-10-04 | 2002-08-22 | Rubenstein Ronald C. | Compositions and methods for treatment of cystic fibrosis |
US7291619B2 (en) | 2001-01-23 | 2007-11-06 | Eli Lilly And Company | Melanocortin receptor agonists |
DE10105337A1 (de) * | 2001-02-05 | 2002-08-08 | Josef Scherer | Tragelement und Tragelementanordnung, insbesondere für Betonbauwerke und Betonbauteile |
WO2002062766A2 (en) | 2001-02-07 | 2002-08-15 | Millennium Pharmaceuticals, Inc. | Melanocortin-4 receptor binding compounds and methods of use thereof |
ATE430565T1 (de) | 2001-02-28 | 2009-05-15 | Merck & Co Inc | Acylierte piperidinderivate als melanocortin-4- rezeptoragonisten |
US7015235B2 (en) | 2001-02-28 | 2006-03-21 | Merck & Co., Inc. | Acylated piperidine derivatives as melanocortin-4 receptor agonists |
CA2438272A1 (en) | 2001-03-02 | 2002-10-10 | John Macor | Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same |
GB0108631D0 (en) | 2001-04-05 | 2001-05-30 | Melacure Therapeutics Ab | Novel benzylideneamino guanidines and their uses as ligands to the melanocortin receptors |
EP1767525A1 (de) | 2001-04-09 | 2007-03-28 | Novartis Vaccines and Diagnostics, Inc. | Guanidinoverbindungen als Melanocortin-4-Rezeptor (MC4-R) Agonisten |
JP4010951B2 (ja) | 2001-05-15 | 2007-11-21 | 大正製薬株式会社 | アルギニン誘導体 |
WO2003006604A2 (en) * | 2001-07-12 | 2003-01-23 | Merck & Co., Inc. | Cyclic peptides as potent and selective melanocortin-4 receptor agonists |
JP4336196B2 (ja) | 2001-07-18 | 2009-09-30 | メルク エンド カムパニー インコーポレーテッド | メラノコルチン受容体作動薬としての架橋ピペリジン誘導体 |
US7115607B2 (en) | 2001-07-25 | 2006-10-03 | Amgen Inc. | Substituted piperazinyl amides and methods of use |
US6977264B2 (en) | 2001-07-25 | 2005-12-20 | Amgen Inc. | Substituted piperidines and methods of use |
US7695917B2 (en) | 2001-10-09 | 2010-04-13 | Oregon Health & Science University | Rescue of gonadotropin releasing hormone receptor mutants |
US20030158209A1 (en) | 2001-10-09 | 2003-08-21 | Neurocrine Biosciences Inc. | Ligands of melanocortin receptors and compositions and methods related thereto |
DK1446394T3 (da) | 2001-11-08 | 2007-03-12 | Ortho Mcneil Pharm Inc | Hidtil ukendte 1,2,4-thiadiazolderivater som melanocortinreceptormodulatorer |
US7319107B2 (en) | 2001-11-08 | 2008-01-15 | Johnson & Johnson Consumer Companies, Inc. | 1,2,4-thiadiazolium derivatives as melanocortin receptor modulators |
MXPA04005999A (es) | 2001-12-21 | 2005-07-13 | Taisho Pharma Co Ltd | Derivado de piperazina. |
ES2274201T3 (es) | 2002-01-23 | 2007-05-16 | Eli Lilly And Company | Agonistas del receptor de melanocortina. |
US20030195187A1 (en) | 2002-02-04 | 2003-10-16 | Chiron Corporation | Guanidino compounds |
US20030207814A1 (en) | 2002-02-04 | 2003-11-06 | Chiron Corporation | Novel guanidinyl derivatives |
WO2003068738A1 (en) | 2002-02-11 | 2003-08-21 | Neurocrine Biosciences, Inc. | Pyrrole derivatives as ligands of melanocortin receptors |
US20030229025A1 (en) | 2002-02-25 | 2003-12-11 | Chiron Corporation | Intranasal administration of MC4-R agonists |
US20040010010A1 (en) | 2002-04-30 | 2004-01-15 | Ebetino Frank Hallock | Melanocortin receptor ligands |
US7026335B2 (en) | 2002-04-30 | 2006-04-11 | The Procter & Gamble Co. | Melanocortin receptor ligands |
JP2005534632A (ja) * | 2002-05-10 | 2005-11-17 | ニューロクライン バイオサイエンセズ, インコーポレイテッド | メラノコルチンレセプターリガンドとしての置換ピペラジン |
US20060183789A1 (en) * | 2002-09-25 | 2006-08-17 | Lavanya Rajachandran | Methods for preventing and treating obesity in patients with mc4 receptor mutations |
CA2514449A1 (en) | 2003-01-29 | 2004-08-19 | Oregon Health And Science University | Restoring function to gonadotropin releasing hormone receptor mutants |
EP1468999A1 (de) * | 2003-03-20 | 2004-10-20 | MyoContract Ltd. | Substituierte Piperidin- und Piperazin-Derivative als Melanocortin-4 Receptor Modulatoren |
-
2006
- 2006-06-02 US US11/446,429 patent/US20070021433A1/en not_active Abandoned
- 2006-06-05 WO PCT/US2006/021752 patent/WO2006133098A2/en active Application Filing
- 2006-06-05 EP EP15153180.3A patent/EP2933265B1/de not_active Not-in-force
- 2006-06-05 MX MX2007015225A patent/MX2007015225A/es active IP Right Grant
- 2006-06-05 AU AU2006255131A patent/AU2006255131B2/en not_active Ceased
- 2006-06-05 KR KR1020087000146A patent/KR20080034877A/ko not_active Application Discontinuation
- 2006-06-05 ES ES15153180T patent/ES2710675T3/es active Active
- 2006-06-05 EP EP06772163.9A patent/EP1885366B1/de not_active Not-in-force
- 2006-06-05 ES ES06772163.9T patent/ES2676996T3/es active Active
- 2006-06-05 CA CA2610860A patent/CA2610860C/en not_active Expired - Fee Related
- 2006-06-05 CA CA2930810A patent/CA2930810C/en not_active Expired - Fee Related
- 2006-06-05 JP JP2008514960A patent/JP5241490B2/ja active Active
-
2007
- 2007-12-02 IL IL187806A patent/IL187806A/en active IP Right Grant
-
2009
- 2009-08-03 US US12/534,665 patent/US9381194B2/en active Active
-
2012
- 2012-11-05 JP JP2012243680A patent/JP6119960B2/ja active Active
-
2015
- 2015-09-14 JP JP2015180996A patent/JP2016040259A/ja active Pending
- 2015-11-12 IL IL242570A patent/IL242570A/en active IP Right Grant
-
2016
- 2016-04-08 HK HK16104050.1A patent/HK1216256A1/zh not_active IP Right Cessation
- 2016-05-06 US US15/148,693 patent/US9937165B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
WO2006133098A3 (en) | 2009-05-07 |
JP5241490B2 (ja) | 2013-07-17 |
AU2006255131B2 (en) | 2012-12-13 |
CA2930810A1 (en) | 2006-12-14 |
WO2006133098A2 (en) | 2006-12-14 |
US9381194B2 (en) | 2016-07-05 |
AU2006255131A1 (en) | 2006-12-14 |
EP2933265A2 (de) | 2015-10-21 |
US20070021433A1 (en) | 2007-01-25 |
IL242570A (en) | 2017-06-29 |
EP1885366A4 (de) | 2010-07-14 |
US20090312345A1 (en) | 2009-12-17 |
EP1885366B1 (de) | 2018-05-30 |
EP2933265A3 (de) | 2015-12-30 |
MX2007015225A (es) | 2008-02-22 |
JP2013067626A (ja) | 2013-04-18 |
JP2016040259A (ja) | 2016-03-24 |
IL187806A0 (en) | 2008-11-03 |
IL187806A (en) | 2017-07-31 |
EP1885366A2 (de) | 2008-02-13 |
JP6119960B2 (ja) | 2017-04-26 |
ES2676996T3 (es) | 2018-07-27 |
US9937165B2 (en) | 2018-04-10 |
HK1216256A1 (zh) | 2016-10-28 |
CA2610860A1 (en) | 2006-12-14 |
US20160287581A1 (en) | 2016-10-06 |
CA2610860C (en) | 2016-07-26 |
CA2930810C (en) | 2018-03-06 |
JP2009509912A (ja) | 2009-03-12 |
KR20080034877A (ko) | 2008-04-22 |
EP2933265B1 (de) | 2018-11-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2710675T3 (es) | Chaperonas farmacológicas para el tratamiento de la obesidad | |
Lin et al. | Role of P-glycoprotein in pharmacokinetics: clinical implications | |
Cheng et al. | Expression of organic anion transporter 2 in the human kidney and its potential role in the tubular secretion of guanine-containing antiviral drugs | |
Chruscicka et al. | Attenuation of oxytocin and serotonin 2A receptor signaling through novel heteroreceptor formation | |
ES2595579T3 (es) | Agente tipo SorCS1 para su uso en el tratamiento de la resistencia a la insulina y enfermedades relacionadas con la misma | |
Finetti et al. | The intraflagellar transport protein IFT20 recruits ATG16L1 to early endosomes to promote autophagosome formation in T cells | |
PT1577320E (pt) | Péptidos derivados da proteína bplp humana, polinucleótidos que codificam para os referidos péptidos e anticorpos dirigidos contra os referidos péptidos | |
EP3373947B1 (de) | Verbindungen und verfahren zur behandlung von schmerz | |
US20220273751A1 (en) | Gpcr heteromer inhibitors and uses thereof | |
Boyanova | Interaction of amisulpride with transporters at the blood-brain barrier. Relevance to Alzheimer’s | |
Moulton et al. | Dominant Missense Variants in SREBF2 are Associated with Complex Dermatological, Neurological, and Skeletal Abnormalities | |
US20110268736A1 (en) | Method for treating congenital myopathy | |
US8148095B2 (en) | Methods for predicting psychotropic drugs which elicit weight gain | |
US7238708B2 (en) | Glucose sensor | |
Wang | Pharmacological characterization and functional rescue of the giant panda and human melanocortin-4 receptors | |
CN101535342A (zh) | 用于治疗肥胖的药理学陪伴分子 | |
Sakrikar | Paying attention to the details: rare genetic variation in the dopamine transporter and ADHD | |
Costales | Cation-selective Apical Transporters Mediate an Intestinal Cycling Mechanism of Metformin that Enhances its Paracellular Oral Absorption in Mice | |
Giri | Targeted delivery of anti-retroviral nucleosides: Role of breast cancer resistance protein | |
Maghnie et al. | Disorders of salt and water balance in children |